Extrapyramidal side effects as a consequence of treatment with neuroleptics

Extrapyramidal side effects as a consequence of treatment with neuroleptics

Objective: To check the occurrence of extrapyramidal side effects inpatients receiving neuroleptic drugs, how these effects are treated,and to observe the occurrence of hallucinations caused by treatmentof extrapyramidal symptoms. Methods: The present study analyzedmedical records and interviewed 39...

Full description

Bibliographic Details
Main Authors:	Shirley Fumi Taniguchi, Maria de Lourdes Rabelo Pequeno, Wanessa Alves Frederico, Seizi Oga
Format:	Article
Language:	English
Published:	Instituto Israelita de Ensino e Pesquisa Albert Einstein 2008-03-01
Series:	Einstein (São Paulo)
Subjects:	Antipsychotic agents/adverse effects Cholinergic antagonists Biperiden/therapeutic use Schizophrenia/drug therapy
Online Access:	http://www.einstein.br/revista/arquivos/PDF/695-Einstein%20v6n1p51-5.pdf

Similar Items

Anticholinergic Plant Misuse and Schizophrenia: Regarding a Case Report
by: Pedro Frias Gonçalves, et al.
Published: (2021-09-01)

Effect of Ginkgo biloba, Risperidone and Biperiden regimen in chronic schizophrenia
by: Nikfarjam M (MD), et al.
Published: (2012-05-01)

The interaction of folate cycle enzyme genes and the risk of extrapyramidal side effects of antipsychotics
by: T. V. Zhilyaeva, et al.
Published: (2020-12-01)

Clozapine Induced Oculogyric Crisis, A Case Report
by: E. Salehifar, Pharm.D. , BCPS, et al.
Published: (2007-01-01)

Clinical assessment of antipsychotic-induced extrapyramidal symptoms in nursing home residents with schizophrenia
by: Karol Woźniak, et al.
Published: (2016-03-01)

CYP2D6 GENETIC POLYMORPHISM AND EXTRAPYRAMIDAL SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS
by: Vita Dolžan, et al.
Published: (2002-07-01)

Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients
by: Dieter Naber, et al.
Published: (2009-10-01)

Extrapyramidal side effects with low dose amisulpride: A report of two cases
by: Pattath Narayanan Suresh Kumar, et al.
Published: (2016-01-01)

Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia
by: Barteček Richard, et al.
Published: (2011-10-01)

Risperidone-Associated Neuroleptic Malignant Syndrome in an Inpatient With Schizophrenia, With Successful Rechallenge and 3 Year Follow-Up
by: Ting-Ren Chen, et al.
Published: (2018-12-01)

A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers
by: Demet Sağlam Aykut, et al.
Published: (2018-07-01)

Aripiprazole-induced skin rash
by: Santanu Nath, et al.
Published: (2016-01-01)

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting
by: Clément François, et al.
Published: (2017-01-01)

Salivary flow rate and decayed, missing, and filled teeth (DMFT) in female patients with schizophrenia on chlorpromazine therapy
by: Jelena Krunić, et al.
Published: (2013-12-01)

Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation
by: Jan Svoboda, et al.
Published: (2017-11-01)

Solubility enhancement of biperidine HCl by complexation with hydroxypropyl β-cyclodextrin
by: Amit Dubey, et al.
Published: (2015-05-01)

Identification of Antipsychotic Side Effects with Glassgow Antipsychotic Side-Effect Scale (GASS)
by: Dita Hasni, et al.
Published: (2020-08-01)

Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin
by: Marcelo Passos Teivelis, et al.
Published: (2014-09-01)

Unilateral mydriasis secondary to ipratropium bromide in a critically ill patient
by: Luciano Santana-Cabrera, et al.
Published: (2012-01-01)

Efficacy of Anticholinergics for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Young and Middle-Aged Patients: A Single-Blinded, Prospective, Multi-Center Study
by: Doo Sang Kim, et al.
Published: (2011-09-01)

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
by: Greg W. Mattingly, et al.
Published: (2020-05-01)

Darifenacin in a real-world practice: results of a 6-month phase IV. trial
by: Tine Hajdinjak, et al.
Published: (2013-05-01)

Animal models for predicting the efficacy and side effects of antipsychotic drugs
by: Pedro H. Gobira, et al.
Published: (2013-01-01)

Anticholinergic Drugs – Functional Antidotes for the Treatment of Tabun Intoxication
by: Gabriela Krejčová, et al.
Published: (2004-01-01)

Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study
by: Weng JJ, et al.
Published: (2019-08-01)

Second generation antipsychotics causing neuroleptic malignant syndrome
by: C. Suraweera, et al.
Published: (2016-12-01)

Alpha7 Nicotinic Acetylcholine Receptor Is a Target in Pharmacology and Toxicology
by: Miroslav Pohanka
Published: (2012-02-01)

Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study
by: Merhawi Bahta, et al.
Published: (2021-04-01)

Neuroleptic malignant syndrome
by: Bino Rajamani, et al.
Published: (2016-01-01)

A single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia
by: Amrita Prakash Singam, et al.
Published: (2011-01-01)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
by: David D. Kim, et al.
Published: (2021-07-01)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
by: Hong Jihyung, et al.
Published: (2012-12-01)

Antipsicóticos de ação prolongada no tratamento de manutenção da esquizofrenia: Parte I. Fundamentos do seu desenvolvimento, benefícios e nível de aceitação em diferentes países e culturas
by: Luiz Paulo de C. Bechelli

Effects of Terazosin and Tolterodine on Ureteral Stent Related Symptoms: A Double-Blind Placebo-Controlled Randomized Clinical Trial
by: Ali Tehranchi, et al.
Published: (2013-12-01)

Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study
by: Bahta M, et al.
Published: (2020-10-01)

Pharmacogenetics and Antipsychotic Treatment in Schizophrenia with Special Focus on Adverse Drug Reactions
by: Gunes, Arzu
Published: (2008)

Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway
by: Saki Shimizu, et al.
Published: (2017-07-01)

Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews
by: Tamara Melnik, et al.

Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies
by: Mitsukuni Murasaki, et al.
Published: (2021-09-01)

Cholinergic and dopaminergic effects on prediction error and uncertainty responses during sensory associative learning
by: Sandra Iglesias, et al.
Published: (2021-02-01)